MedinCell S.A. (EPA:MEDCL)
France · Delayed Price · Currency is EUR 26.88
-0.22 (-0.81%)
Jul 13, 2026, 5:35 PM CET
MedinCell Income Statement
Financials in millions EUR. Fiscal year is April - March.
Millions EUR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 19.52 | 25.42 | 9.03 | 9.89 | 4.09 |
Other Revenue | 4.76 | 2.31 | 2.91 | 3.77 | 4.25 |
| 24.28 | 27.73 | 11.95 | 13.66 | 8.34 | |
Revenue Growth (YoY) | -12.44% | 132.12% | -12.52% | 63.77% | 1.86% |
Gross Profit | 24.28 | 27.73 | 11.95 | 13.66 | 8.34 |
Selling, General & Admin | 18.48 | 14.18 | 11.79 | 9.72 | 8.49 |
Research & Development | 26.54 | 24.31 | 21.05 | 27.92 | 23.58 |
Other Operating Expenses | - | - | 0.04 | 0.04 | 0.08 |
Operating Expenses | 45.02 | 38.49 | 32.89 | 37.68 | 32.15 |
Operating Income | -20.74 | -10.76 | -20.94 | -24.03 | -23.81 |
Interest Expense | -5.51 | -5.09 | -4.62 | -3.93 | -1.84 |
Interest & Investment Income | 1.36 | 1.4 | 0.55 | 0.04 | 0.05 |
Currency Exchange Gain (Loss) | - | -0.23 | 0.14 | 1.17 | 0.83 |
Other Non Operating Income (Expenses) | -6.43 | -3.52 | -0.04 | -5.21 | -0.02 |
EBT Excluding Unusual Items | -31.32 | -18.2 | -24.91 | -31.95 | -24.8 |
Gain (Loss) on Sale of Investments | - | - | - | -0.04 | - |
Other Unusual Items | -0.04 | -0.08 | -0.04 | -0.02 | -0 |
Pretax Income | -31.36 | -18.28 | -24.95 | -32.01 | -24.81 |
Income Tax Expense | -0.07 | 0.16 | 0.09 | - | - |
Earnings From Continuing Operations | -31.29 | -18.44 | -25.04 | -32.01 | -24.81 |
Net Income | -31.29 | -18.44 | -25.04 | -32.01 | -24.81 |
Net Income to Common | -31.29 | -18.44 | -25.04 | -32.01 | -24.81 |
Shares Outstanding (Basic) | - | 30 | 28 | 25 | 25 |
Shares Outstanding (Diluted) | - | 30 | 28 | 25 | 25 |
Shares Change (YoY) | - | 4.28% | 12.83% | 1.39% | 12.79% |
EPS (Basic) | - | -0.62 | -0.88 | -1.27 | -1.00 |
EPS (Diluted) | - | -0.62 | -0.88 | -1.27 | -1.00 |
Free Cash Flow | -24.55 | 18.72 | -12.25 | -21.58 | -22.99 |
Free Cash Flow Per Share | - | 0.63 | -0.43 | -0.86 | -0.93 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -85.44% | -38.81% | -175.30% | -175.94% | -285.58% |
Profit Margin | -128.88% | -66.50% | -209.61% | -234.42% | -297.50% |
Free Cash Flow Margin | -101.14% | 67.51% | -102.52% | -158.04% | -275.67% |
EBITDA | -20.05 | -10.07 | -20.05 | -23.05 | -22.95 |
EBITDA Margin | -82.60% | -36.32% | -167.83% | -168.81% | -275.23% |
D&A For EBITDA | 0.69 | 0.69 | 0.89 | 0.97 | 0.86 |
EBIT | -20.74 | -10.76 | -20.94 | -24.03 | -23.81 |
EBIT Margin | -85.44% | -38.81% | -175.30% | -175.94% | -285.58% |
Revenue as Reported | 24.28 | 27.73 | 11.95 | 13.66 | 8.34 |